First Patient Dosed in Early Trial Testing ORIC-101, Xtandi Combo for Metastatic Prostate Cancer

First Patient Dosed in Early Trial Testing ORIC-101, Xtandi Combo for Metastatic Prostate Cancer
A Phase 1b trial has started dosing patients to study whether Oric Pharmaceutical’s ORIC-101 — which inhibits the glucocorticoid receptor — is able to overcome prostate cancer resistance to Xtandi (enzalutamide), the company announced. The trial (NCT04033328) is testing a combination of ORIC-101 plus Xtandi in men whose metastatic prostate cancer is progressing while on Xtandi treatment. Ongoing at the Carolina Urologic Research Center, in South Carolina, it is expected to recruit a total of 90 participants. More information on enrollment can be found here. "Despite the introduction of novel antiandrogen therapies for the treatment of prostate cancer, such as enzalutamide, the majority of responsive patients will ultimately become treatment resistant, resulting in poor prognoses for men diagnosed with this devastating condition," Pratik S. Multani, MD, chief medical officer at Oric, said in a press release. "We are excited to evaluate the therapeutic potential of ORIC-101 t
Subscribe or to access all post and page content.